Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 71 clinical trials
Featured trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors

  • 0 views
  • 19 Jun, 2022
  • 16 locations
Featured trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Product in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Product in Patients With Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

  • 704 views
  • 25 Mar, 2021
  • 1 location
Featured trial
A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension

A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension

  • 163 views
  • 08 Dec, 2020
  • 1 location
Featured trial
Do you suffer from Hemorrhoids?

Do you suffer from Hemorrhoids?

  • 1549 views
  • 25 Mar, 2021
  • 1 location
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell

pembrolizumab
mk-3475
cancer
adjuvant therapy
  • 117 views
  • 28 Jun, 2022
  • 128 locations
Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

The purpose of this study is to evaluate the safety and efficacy of IBI318 (anti-PD-1/PD-L1) in adult participants with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or

  • 0 views
  • 27 Jan, 2021
  • 1 location
A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

The purpose of this trial is to evaluate safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with cutaneous squamous cell carcinoma

  • 0 views
  • 19 Jun, 2022
  • 7 locations
Intralesional 5-Fluorouracil (5FU), Topical Imiquimod Treatment for SCC

This clinical trial proposes to evaluate a relatively unexplored approach to treatment of squamous cell carcinoma (SCC) on the lower extremities. The strategy is to directly and specifically deliver drug to the tumor. For the proposed phase I clinical trial, the investigators will perform intralesional injections of a well characterized, …

fluorouracil
Accepts healthy volunteers
imiquimod
antineoplastic
  • 284 views
  • 12 Feb, 2022
  • 1 location
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Primary Objective: -To determine the antitumor activity of SAR444245 in combination with cemiplimab. Secondary Objectives: To determine the recommended phase 2 dose and to assess the safety profile of SAR444245 when combined with cemiplimab To assess other indicators of antitumor activity To assess the concentrations of SAR444245 when given in …

measurable disease
metastatic melanoma
metastasis
  • 0 views
  • 19 Jun, 2022
  • 30 locations
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Primary Objective: -To determine the antitumor activity of SAR444245 in combination with cemiplimab. Secondary Objectives: To determine the recommended phase 2 dose and to assess the safety profile of SAR444245 when combined with cemiplimab To assess other indicators of antitumor activity To assess the concentrations of SAR444245 when given in …

measurable disease
metastatic melanoma
metastasis
  • 0 views
  • 10 Jun, 2022
  • 33 locations